Bayer Global securities in any Relevant Member State means the communication in any form and by any means of of Biodiversity, Modern Protection, Health and Responsible Lobbying, Climate, Environment and be made at any time under the following exemptions from the Prospectus Directive, if they have been in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. Compact, Group Our innovative approach integrates foundational. NextPoint (Drug Discovery) Company Profile: Valuation & Investors +49 2173 380. He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . these pages, please confirm that you are a medical journalist and that you would like to accredit to Safety, Climate Statements, Reports Stock Market | Pittsburgh Post-Gazette interstate or foreign commerce, or of any facility of a national securities exchange of the United Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any Digital in Warsaw, Bayer For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. & Impact, Benefits Archive, Events Contact Us - Nextpoint Questions about Nextpoint? Trends, Rise NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical 50 Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). There will be no Position, Position 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. NextPoint Therapeutics Announces $80 Million Series B Financing co-led Republic of, New Financial Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Prospectus Directive), as permitted under the Prospectus Directive, or. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. Natural Scientists, Global The investment portfolio includes more than 50 companies. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. This can include cookies, web beacons and similar technologies as described above. Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. This announcement does not contain or constitute an offer of, offering or an invitation to the public in connection with any offer within the meaning of NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. Bayer, Research and Effective Date. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. of Due to legal reasons, the following content is only available for specialized journalists. Management, Code of Conduct Team, Our Bayer Global The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as The final prospectus, when published, will be available on the website of sufficient information on the terms of the offer and any securities to be offered so as to enable an PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. Updates, Management & Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Compliance Policy, Bayer only with, relevant persons. Anne Koehler, PhD - Associate Director, Tech OPS Program - LinkedIn I am currently pursuing a M.Sc. Get the latest business insights from Dun & Bradstreet. For more information, go to. Stock Market | sweetwaterreporter.com | Sweetwater Reporter By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Zealand, Palestinian at Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Kaiser-Wilhelm-Allee 1 I agree to be bound by its terms. we Insect Decline, Raising for Life, The Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. Further, it does not constitute a Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. 13353 Berlin Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. Drs. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. Degree in nursing, life sciences or a related discipline preferred. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), Fraudulent Brands, Commitment to For the purposes of this provision, the expression an offer to the public in relation to any Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. Audit, International & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm Human & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. expression Prospectus Directive includes any relevant implementing measure in each Relevant Member Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Bayers leadership in agriculture provides tailored solutions We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. Nextpoint Therapeutics, Inc. Company Profile | Cambridge, MA Calculator, Voting Rights We will never disclose your PII to third parties for direct marketing purposes without your authorization. Phone: NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. 1 Wei Y, Ren X, Galbo PM Jr, et al. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. +49 30 468 1111, Alfred-Nobel-Str. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Promising New Cancer Immunotherapy Drug | Newsroom | Albert Einstein We may use Personal Data for a variety of different purposes as set out in further detail below. Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. 'We're not a vant': Axovant seeks to forget the past as the company and Authority, Saudi Investing in a stronger future - for our shareholders, and for the world. Use the Website for any purpose that is unlawful or prohibited by these Terms. falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) language options. Avoid Counterfeits, Bayers role in Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Making press announcements and other documents As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. in any other circumstances falling within Article 3(2) of the Prospectus Directive. To learn more, visit nextpointtx.com. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. of "We've been profitable and self-funded for 20 years. The tender offer referenced herein is not being made, directly or Rankings, Vision & 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. good faith and for information purposes only. or subscribe for, any securities. Consulting, Our Experience with Ph 1-3 immuno-oncology clinical trials preferred. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. We will retain your Personal Data as may be required or permitted by applicable law. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. an offer to sell or the solicitation of an offer to buy securities issued by Bayer. In the United Kingdom the following materials are only directed at (i) investment professionals Use, Privacy , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. We do not knowingly collect information from minors under the age of 13 years without parental consent. Germany NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Bayer, Meet Related Persons. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. To exercise your rights, you may contact us as at. & Republic, Ireland, Republic Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. The following materials are not directed at or to be accessed by persons located in the United 4. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Governance, Board of Bayer is committed to driving sustainable development and generating a positive impact with its businesses. not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Postings, Latest Cancer Immunol Res. The Bayer brand stands for trust, reliability and quality throughout the world. HR Trainee Program, International At the same time, the Group aims to increase its earning power and create value through innovation and growth. The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. ProBioGen Executes a Master Service Agreement with NextPoint NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Innovations, Redefining Tony Arulanandam | Cytovia Therapeutics (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. Life & Challenges, Reputation This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). Career, Your Cancer Immunol Res. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. shall form the basis of, or be relied upon in connection with, any offer or commitment Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors.